May 2025 highlights: merging innovation with action
Introducing Augusta, our precision neurology platform
We recently launched Augusta, our new precision neurology platform built to accelerate patient stratification, biomarker discovery, and drug development for neurological diseases – especially in complex conditions like Parkinson’s disease and epilepsy.
Powered by our validated Cube and Elion platforms, Augusta combines multimodal analytics and proprietary in silico screening to fast-track therapeutic development. Its unique modular pipeline includes
- Patented, bias-reducing data preprocessing
- Phenoclustering to define clinically and biologically meaningful subgroups
- Biomarker identification using clinical and molecular data
- In silico compound screening powered by generative modeling
- In vivo CRISPR-based in vivo validation supercharged by computer vision
Augusta is interpretable and benchmarked – and it’s already delivering validated insights for precision neurology.
Partnering with Amsterdam UMC on platelet RNA diagnostics
We announced a four-year exclusive partnership with Amsterdam UMC to co-develop blood platelet RNA diagnostics – a novel, minimally invasive approach to detect and monitor disease, with an initial focus on cancer.
This effort integrates Renovaro’s AI/ML strengths and new compute infrastructure infrastructure, via Nebul, to extract disease-specific signals from blood samples. The collaboration spans sample collection, multimodal data integration, and development of deep learning models.
Scaling Elion to improve mechanism of action predictions
Victoria Catterson, VP of Data Science Research at BioSymetrics (a subsidiary of Renovaro), dramatically expanded Elion’s chemical search space by integrating the ZINC-20 dataset – growing its “chemical white space” from 1 million to an astounding 557 million compounds without adding new target annotations.
Even without changing the models or annotations, this leap improved Elion’s ability to predict mechanisms of action (MOA) – a critical step in early drug discovery. Key improvements included
- More accurate target predictions
- Higher target rankings
- Increased frequency of correct targets among top results
This simple expansion of chemical diversity enhances confidence in early predictions, which will enable faster and cheaper drug development.
Read the full blog post on BioSymetrics' website.
Podcast: merging science and strategy
David Weinstein (Renovaro CEO) and Gabe Musso (BioSymetrics CSO) shared on The Wall Street Resource how Renovaro and BioSymetrics are redefining precision medicine. They discussed how our integrated platform – combining Contingent AI and zebrafish in vivo testing – tackles efficacy and toxicity head-on.
Their conversation covered
- The data-first philosophy behind our approach
- Applications in oncology and neurology
- How our end-to-end system predicts and validates drug effects quickly and cost-effectively, enabling faster, more tailored therapies
Listen on The Wall Street Resource or your favorite podcast app: Spotify | Apple Podcasts | Pocket Casts
Meet us at BIO 2025 in Boston, June 16–19
Gabe Musso (BioSymetrics CSO) will be at BIO International Convention 2025 in Boston from June 16–19.
If you are attending and interested in partnerships, AI-powered drug development, or precision medicine strategy – particularly in oncology and neurology – we would love to connect. Book a meeting with Gabe through the BIO Partnering system to explore potential collaborations.
New look, new channels
Our website has a fresh new look – with special thanks to Oslop Studio for their help on the redesign and rebranding.
We’d love for you to stay connected with us. Follow and tag us on LinkedIn, X (formerly Twitter), Bluesky, and Threads as we continue improving outcomes for cancer and neurology patients – from early screening to diagnosis and treatment.
